Opinion: STAT+: The real work for making dramatic gains against pancreatic cancer is just beginning

A UCLA-led study found that pancreatic cancer patients taking daraxonrasib lived an average of 13.2 months, compared to 6.6-6.7 months with chemotherapy alone. The FDA granted early access to the drug for patients who failed standard treatments, as reported at the ASCO meeting in Chicago.